Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to compare in Tramadol, Naproxen sodium and Placebo in participants presenting with irreversible pulpitis in their mandibular molar teeth.
The main question[s] it aims to answer are:
Researchers will compare Tramadol, Naproxen sodium and Placebo to evaluate their effects on Inferior alveolar nerve block efficacy and Postoperative pain.
The adult participants who report in out-patient department (OPD) of Operative Dentistry at Dow International Dental College with the symptoms of irreversible pulpitis will be screened for the participation in the study. A detailed history will be taken which will be followed by clinical examination and complemented with sensibility testing with Endo Ice or electric pulp test. Radiographic analysis will also be done to confirm the diagnosis to assess for factors pertaining to exclusion and inclusion criteria. Verbal and written informed consent will be taken from all the participants.
Randomization: The participants will be randomly divided into 3 groups using a computer-generated randomization sequence (Microsoft Excel, Redmond, WA). The sequence was generated employing block randomization with an equal allocation ratio (1:1:1).
Group A will receive premedication of Oral tramadol 100mg, Group B will receive premedication of oral naproxen 550mg. Both medicines will be given 60 minutes prior to the local anesthesia administration. The third group, Group C, will be the control group and no active preoperative medication will be given to these participants. A placebo will be given to these participants. These medications will be given as a single intervention only.
Blinding: operator, participant and outcome assessor will be blinded. A paramedical staff will be trained in giving medication to the participants.
Pain scores will be recorded by asking the participant to rate their pain on a scale ranging from 0 to 10 before medication and then after 15 minutes, 30 minutes and 60 minutes of administering the premedication. Pain score will also be recorded after 10 minutes of the administration of Inferior alveolar nerve block (IANBs) and buccal nerve block & during deroofing process of chamber opening. This step will serve as our primary outcome measure as anasthesia success rate.
Two cartridges of Lidocaine 1.8 ml having a concentration of 1:100,000 of Epinephrine will be used for administration of regional anesthesia. Access opening will be performed under rubber dam isolation with a round bur in a high-speed hand piece with copious water irrigation. Sodium hypochlorite (5.25%) will be used as a standard root canal irrigation solution.Pulpectomy will be performed with the Protaper universal file system until the working lengths of the teeth under study.
To assess the post-operative pain, a proforma and pain intensity scale will be provided to the participants for self recording at 6, 24, 48 and 72 hours after the procedure. The participants will return the proforma to an intern on 4th day to be assessed by an intern supervised by the principal investigator and assesed as secondary outcome of our study.
(For this research, "The investigators will be offering As per need analgesic for breakthrough pain. Participants will be offered brufen 400mg as needed. The participants will be advised to mark breakthrough pain on VAS at the time of taking medicine).
The participants will also be monitored for the adverse effects of these medications (nausea, vomiting, dizziness, drowsiness).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Tramadol | Active Comparator | Group A will receive premedication of Oral tramadol 100mg, |
|
| Naproxen Sodium | Active Comparator | Group B will receive premedication of oral naproxen sodium 550mg. |
|
| Placebo | Placebo Comparator | Group C, will be the control group, and Surbex-Z will be given to these patients. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tramadol | Drug | Tramadol 100mg will be given 60 minutes before start of procedure. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Local Anesthesia Efficacy | Local anesthesia efficacy was defined as absence of pain (VAS score ≤ 3) during access cavity preparation (deroofing) after inferior alveolar nerve block. Pain was assessed using a 10-point Visual Analog Scale (0 = no pain, 10 = worst pain). Participants were categorized as having successful anesthesia if VAS ≤ 3 and failure if VAS > 3. | During access cavity preparation (deroofing) |
| Measure | Description | Time Frame |
|---|---|---|
| Postoperative Pain | Postoperative pain was assessed using a 10-point Visual Analog Scale (VAS), where 0 indicates no pain and 10 indicates the worst possible pain. Higher scores represent greater pain intensity. Pain scores were recorded at 6, 24, 48, and 72 hours postoperatively. Results are presented as median pain scores at each time point. | 6,24,48,72 hours post operatively |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Tayyaba Tahira, BDS FCPS | Dow International Dental College, Dow University of Health Sciences | Principal Investigator |
| Farah Naz, BDS FCPS | Dow International Dental College, Dow University of Health Sciences | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dow International Dental College | Karachi | Sindh | 75500 | Pakistan |
Only investigators and co-investigators of this study will be able to access to participants' personal data.
Ownership of the data will remain with the principal investigator and Department of Operative Dentistry, Dow International Dental College
Not provided
Not provided
Not provided
Not provided
Of 145 eligible patients, 139 consented to participate in the study and to undergo the anesthetic and endodontic procedures. However, only 120 patients were evaluated for anesthetic efficacy and postoperative pain. This was due to 12 patients not recording VAS readings, 2 being excluded after access cavity preparation because of a lack of bleeding to confirm pulp vitality, and 5 requiring rescue medication after root canal treatment. Consequently, data from 120 patients were analyzed (Figure 1).
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Tramadol | Group A will receive premedication of Oral tramadol 100mg, |
| FG001 | Naproxen Sodium | Group B will receive premedication of oral naproxen sodium 550mg. |
| FG002 | Placebo | Group C, will be the control group, and Surbex-Z will be given to these patients. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Tramadol | Group A will receive premedication of Oral tramadol 100mg, |
| BG001 | Naproxen Sodium | Group B will receive premedication of oral naproxen sodium 550mg. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With Local Anesthesia Efficacy | Local anesthesia efficacy was defined as absence of pain (VAS score ≤ 3) during access cavity preparation (deroofing) after inferior alveolar nerve block. Pain was assessed using a 10-point Visual Analog Scale (0 = no pain, 10 = worst pain). Participants were categorized as having successful anesthesia if VAS ≤ 3 and failure if VAS > 3. | Posted | Count of Participants | Participants | During access cavity preparation (deroofing) |
|
3 days
Participants were followed for a period of 3 days postoperatively for monitoring of adverse effects. Adverse effects were actively assessed, including Nausea, vomiting, dizziness, and headache.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Tramadol | Group A will receive premedication of Oral tramadol 100mg, | 0 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nausea | General disorders | Systematic Assessment | Adverse events were monitored over 3 days via patient reports and questioning. |
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Farah Naz | Dow university of health sciences | 03323461321 | farah.naz@duhs.edu.pk |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan: study protocol and statistical plan | Mar 1, 2023 | Jun 2, 2026 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D010149 | Pain, Postoperative |
| ID | Term |
|---|---|
| D011183 | Postoperative Complications |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010146 | Pain |
Not provided
Not provided
| ID | Term |
|---|---|
| D014147 | Tramadol |
| D009288 | Naproxen |
| ID | Term |
|---|---|
| D003511 | Cyclohexanols |
| D000441 | Hexanols |
| D005233 | Fatty Alcohols |
| D000438 | Alcohols |
| D009930 |
Not provided
Not provided
The participants will be randomly divided into 3 groups. Computer software (Microsoft Excel, Redmond, WA) will be used to generate a random patient allocation sequence.
Group A will receive premedication of Oral tramadol 100mg, Group B will receive premedication of oral naproxen sodium 550mg. Both medicines will be given 60 minutes prior to the local anesthesia administration. The third group, Group C, will be the control group and no active preoperative medication will be given to these participants. A placebo will be given to these participants. These medications will be given as a single intervention only.
Not provided
Not provided
Clinician and participants both will be blind to the medicine given to the participants. Participants will be given identical capsules by paramedical staff will be trained in giving medication to the participants. Outcome Assessor will be an intern who is not on research.
| Naproxen Sodium | Drug | Naproxen sodium 550mg will be given 60 minutes before start of procedure. |
|
|
| Placebo | Drug | Placebo will be given 60 minutes before start of procedure. |
|
|
| BG002 | Placebo | Group C, will be the control group, and Surbex-Z will be given to these patients. |
| BG003 | Total | Total of all reporting groups |
| Years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
|
| Preoperative pain scores on VAS | Pain was assessed using a 10-point Visual Analog Scale (VAS), where 0 indicates no pain and 10 indicates worst possible pain | Median | Inter-Quartile Range | score on scale |
|
| OG002 | Placebo | Group C, will be the control group, and Surbex-Z will be given to these patients. |
|
|
| Secondary | Postoperative Pain | Postoperative pain was assessed using a 10-point Visual Analog Scale (VAS), where 0 indicates no pain and 10 indicates the worst possible pain. Higher scores represent greater pain intensity. Pain scores were recorded at 6, 24, 48, and 72 hours postoperatively. Results are presented as median pain scores at each time point. | Posted | Median | Full Range | score on scale | 6,24,48,72 hours post operatively |
|
|
|
| 40 |
| 0 |
| 40 |
| 8 |
| 40 |
| EG001 | Naproxen Sodium | Group B will receive premedication of oral naproxen sodium 550mg. | 0 | 40 | 0 | 40 | 1 | 40 |
| EG002 | Placebo | Group C, will be the control group, and Surbex-Z will be given to these patients. | 0 | 40 | 0 | 40 | 0 | 40 |
|
Not provided
Not provided
Not provided
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| Organic Chemicals |
| D004123 | Dimethylamines |
| D008744 | Methylamines |
| D000588 | Amines |
| D008055 | Lipids |
| D009280 | Naphthaleneacetic Acids |
| D009281 | Naphthalenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D011083 | Polycyclic Compounds |
| Male |
|
|
| 48 hours post operative pain score |
|
| 72 hours post operative pain score |
|